Jefferies Assumes Atara Biotherapeutics (ATRA) at Buy

October 24, 2016 7:06 AM EDT
Get Alerts ATRA Hot Sheet
Price: $18.65 --0%

Rating Summary:
    4 Buy, 0 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 16 | Down: 19 | New: 15
Trade ATRA Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies assumes coverage on Atara Biotherapeutics (NASDAQ: ATRA) with a Buy rating and a price target of $23.00 (from $25.00).

Analyst Gena Wang commented, "ATRA’s off-the-shelf CTL technology could offer differentiated advantages vs. other T-cell therapies. Promising clinical activity from the lead program EBVCTL in PTLD provides initial proof of concept for the technology platform and we see favorable risk/reward for the pivotal studies. Encouraging initial data from other programs could provide additional upside to the stock. Assuming coverage with a Buy rating and $23 PT."

For an analyst ratings summary and ratings history on Atara Biotherapeutics click here. For more ratings news on Atara Biotherapeutics click here.

Shares of Atara Biotherapeutics closed at $14.90 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, New Coverage

Related Entities

Jefferies & Co, Gena Wang

Add Your Comment